Contract Research and Manufacturing Services (CRAMS) Market
Pharma Outsourcing and CDMO Services
Developing and manufacturing a modern drug is so complex that no single company does it all in house anymore. The global pharma industry relies on a vast ecosystem of Contract Research Organisations (CROs) for clinical trials and Contract Development and Manufacturing Organisations (CDMOs) for producing the actual drug substance and drug product. India is a powerhouse in this sector, offering a compelling value proposition of high quality science at a significantly lower cost base compared to Western markets. The opportunity is moving up the value chain from simple generics to complex injectables, lipid nanoparticles for mRNA delivery, and Antibody Drug Conjugates (ADCs).
What Numbro covers:
Global outsourcing penetration rates by service type: Small Molecule API Manufacturing, Biologics Drug Substance, and Finished Dosage Form Fill Finish. India CRAMS export growth analysis by destination market and therapeutic category. Capability benchmarking of Indian CDMOs in niche areas like sterile injectables, pre filled syringes, and high containment manufacturing for oncology drugs. Impact analysis of the US Biosecure Act and geopolitical shifts favouring Indian CDMOs.
- Global pharma sourcing and procurement teams
- Indian pharma exporters
- Private equity firms rolling up CDMO assets
- Quality and regulatory compliance heads
